Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.77 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.73 |
| ▸ | MEN1 | O00255 | 5/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.67 |
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6720188 | 0.83 | MEN1 (0.81) | GAAL3MBTL1ALDH1A1MEN1KMT2A | |
| SCHEMBL11313942 | 0.82 | LMNA (0.81) | GAAALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL3162482 | 0.80 | MEN1 (0.76) | GAAL3MBTL1ALDH1A1MEN1KMT2A | |
| SCHEMBL11308686 | 0.80 | KMT2A (1.00) | GAAL3MBTL1ALDH1A1MEN1KMT2A | |
| SCHEMBL11305593 | 0.80 | GAA (0.81) | GAAL3MBTL1ALDH1A1MEN1KMT2A | |
| SCHEMBL3157213 | 0.78 | ALDH1A1 (1.00) | GAAL3MBTL1ALDH1A1MEN1KMT2A | |
| SCHEMBL3144217 | 0.76 | MEN1 (0.69) | GAAL3MBTL1ALDH1A1MEN1KMT2A | |
| SCHEMBL11306629 | 0.76 | LMNA (0.81) | GAAALDH1A1MEN1KMT2AMAPT | |
| Propyphenazone SCHEMBL23393 | 0.76 | LMNA (1.00) | GAAALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL3152146 | 0.75 | ALDH1A1 (0.76) | GAAL3MBTL1ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183236-B2 | Compounds with HIV-1 integrase inhibitory activity and use thereof as anti-HIV/AIDS therapeutics | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183236-B2 | Compounds with HIV-1 integrase inhibitory activity and use thereof as anti-HIV/AIDS therapeutics | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2012-05-22 | — | — | US | disclosed |
| US-20090088420-A1 | COMPOUNDS WITH HIV-1 INTEGRASE INHIBITORY ACTIVITY AND USE THEREOF AS ANTI-HIV/AIDS THERAPEUTICS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2009-04-02 | — | — | US | disclosed |
| US-20090088420-A1 | COMPOUNDS WITH HIV-1 INTEGRASE INHIBITORY ACTIVITY AND USE THEREOF AS ANTI-HIV/AIDS THERAPEUTICS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2009-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088420-A1 | COMPOUNDS WITH HIV-1 INTEGRASE INHIBITORY ACTIVITY AND USE THEREOF AS ANTI-HIV/AIDS THERAPEUTICS | TYMP, IMPDH1, SAMHD1 | GAA 67/4885L3MBTL1 217/4885ALDH1A1 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.